We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMED
51
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$10.7M 0.36%
2,620,897
+1,582,608
+152% +$6.89M
TSRO
52
DELISTED
TESARO, Inc.
TSRO
$10.7M 0.36%
129,372
-259,279
-67% -$25.4M
CLLS
53
Cellectis
CLLS
$288M
$10.2M 0.34%
+350,000
New +$9.53M
SNDA icon
54
Sonida Senior Living
SNDA
$1.93B
$9.18M 0.3%
45,345
+8,000
+21% +$1.71M
AGRX
55
DELISTED
Agile Therapeutics
AGRX
$9.09M 0.3%
+1,690
New +$15.7M
AMGN icon
56
Amgen
AMGN
$209B
$8.7M 0.29%
+50,000
New +$8.85M
AVEO
57
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$8.25M 0.27%
295,812
-45,700
-13% -$1.42M
FLXN
58
DELISTED
Flexion Therapeutics, Inc.
FLXN
$7.71M 0.26%
+307,989
New +$7.54M
CDNA icon
59
CareDx
CDNA
$1.83B
$7.64M 0.25%
+1,040,676
New +$6.49M
REGN icon
60
Regeneron Pharmaceuticals
REGN
$72.9B
$7.52M 0.25%
+20,000
New +$8.1M
ATRS
61
DELISTED
Antares Pharma, Inc.
ATRS
$7.45M 0.25%
3,745,662
-608,235
-14% -$1.32M
MRNS
62
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.41M 0.25%
226,933
-136,242
-38% -$3.67M
URGN icon
63
UroGen Pharma
URGN
$1.97B
$7.41M 0.25%
199,014
-70,000
-26% -$2.49M
MTEM
64
DELISTED
Molecular Templates, Inc.
MTEM
$7.25M 0.24%
48,276
– –
BHVN
65
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.04M 0.23%
261,134
-45,000
-15% -$1.24M
OXFD
66
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$6.99M 0.23%
500,356
+35,000
+8% +$513K
FOMX
67
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.71M 0.22%
1,117,324
– –
SYBX
68
DELISTED
Synlogic
SYBX
$6.66M 0.22%
45,757
– –
ABLX
69
DELISTED
Ablynx NV
ABLX
$6.25M 0.21%
+250,000
New +$5.65M
ECYT
70
DELISTED
Endocyte, Inc. Common Stock
ECYT
$6.21M 0.21%
+1,451,700
New +$6.92M
RNAC icon
71
Cartesian Therapeutics
RNAC
$218M
$6.21M 0.21%
21,090
-17,654
-46% -$7.71M
ZYME icon
72
Zymeworks
ZYME
$1.62B
$5.55M 0.18%
777,497
+46,729
+6% +$384K
GMED icon
73
Globus Medical
GMED
$11.1B
$4.65M 0.15%
+113,100
New +$3.96M
CLSD
74
DELISTED
Clearside Biomedical
CLSD
$4.34M 0.14%
41,345
– –
ODT
75
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$3.75M 0.12%
+150,000
New +$3.54M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.